Novo Ventures
VC Fund
Bagsværd, Denmark
Novo Ventures is a VC fund in Bagsværd focused on Biotechnology and Health Care. Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S. Novo A/S was established in 1999 prior to the demerger of Novo Nordisk A/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia. Novo A/S attains these objectives through: compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad. Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets. Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group. The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.
- Total investments:
- 79
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Novo Ventures invests in
Stages Novo Ventures invests in
Countries Novo Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Series A
- $8.5M–$74M
- Series B
- $14M–$75M
- Series C
- $13M–$139M
Investment Focus
Industry
- Biotechnology 54 (68%)
- Health Care 34 (43%)
- Medical 22 (28%)
- Pharmaceutical 22 (28%)
- Therapeutics 19 (24%)
Stage
- Series B 27 (34%)
- Series A 17 (22%)
- Series C 9 (11%)
- Series D 7 (9%)
- Seed 4 (5%)
Country
- United States 37 (47%)
- United Kingdom 9 (11%)
- Switzerland 4 (5%)
- Denmark 3 (4%)
- Canada 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Peter Moldt
Partner
|
Partner | Total investments: 6 | Find email | |
Brigid Hughes
Operations Manager
|
Operations Manager | Total investments: 0 | Find email | |
Eric Shiozaki
Principal
|
Principal | Total investments: 0 | Find email | |
Kasim Kutay
CEO
|
CEO | Total investments: 2 | Find email | |
Peter Bisgaard
Partner & Investment Manager
|
Partner & Investment Manager | Total investments: 19 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $138.6M / Series C / Jan 06, 2023 | ||
| Theraxyte is an innovative nano-drug developer. It focuses on the R&D and application of new nano-drugs, especially innovative drugs. | $10M / Seed / Jul 11, 2022 | ||
| Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $80M / Series B / Sep 16, 2021 | ||
| Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases. | $102M / Series D / Sep 08, 2021 | ||
| Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life ofpatients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting.The company was founded in 2014 and is headquartered in San Diego, California. | $95M / Series B / Dec 09, 2020 | ||
| Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals thatarm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors. | $83M / Series C / Sep 17, 2020 | ||
| F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $60.8M / Private Equity / Aug 12, 2020 | ||
| NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. | $55M / Series B / Jun 03, 2020 | ||
| Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can betranslated to virtually any protein in numerous clinical indications. | $40M / Series B / Sep 11, 2019 | ||
| Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $74.2M / Series A / Jul 31, 2019 | ||
| See all 79 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Novo Ventures invest in?
Novo Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 79 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Novo Ventures invest in?
Novo Ventures typically joins rounds of $8.5M–$74M at Series A, $14M–$75M at Series B and $13M–$139M at Series C. These are whole funding-round sizes, not Novo Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Novo Ventures took part in.
How do I contact Novo Ventures?
Public channels for Novo Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novo Ventures?
The team at Novo Ventures includes Peter Moldt (Partner), Brigid Hughes (Operations Manager) and Eric Shiozaki (Principal), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
